Germany Telemedicine Debate Tests European Cannabis Growth

On the second day of Cannabis Europa 2026 at The Barbican Centre in London, three sessions put real commercial pressure on European medical cannabis operators: Germany’s proposed crackdown on telemedicine prescribing, systemic quality failures running from genetics to the shelf, and a women’s health market finding its first regulatory foothold.

Germany’s Prescribing Model Under Scrutiny

The numbers behind the Germany panel explain its significance. The country imported more than 200 tonnes of medical cannabis in 2025, according to Germany’s Federal Institute for Drugs and Medical Devices — nearly triple the 72 tonnes recorded in 2024. That growth ran on telemedicine platforms and mail-order pharmacy delivery. Germany’s current government has decided that model went too far.

The Federal Ministry of Health’s proposed amendment to Germany’s Medical Cannabis Act, adopted by the Federal Cabinet in October 2025 and sent to parliament for its first reading in December 2025, would require in-person doctor visits for initial prescriptions, limit remote repeat prescribing to patients who had an in-person visit within the past four quarters, and ban mail-order delivery of cannabis flowers. As of the conference, the bill had stalled in the Bundestag since that first reading.

Sascha Mielcarek, CEO of Canify, called it “a bit of a fake discussion, used to trade positions,” and argued the practical effect would be to push patients back toward illicit supply. He doesn’t expect fast movement but flagged the continuing exposure: the law remains active and can be brought before parliament at any time.

Kristine Lütke, a former member of the Bundestag who helped write Germany’s original medical cannabis legislation, was equally unconvinced. She argued that restricting telemedicine and flower delivery would produce no measurable public health improvement — patients would migrate to unregulated supply rather than seek in-person appointments.

Niels Lutzhöft, a partner at Bird & Bird, laid out the legal case against the draft. Germany’s own decision to deschedule cannabis from its narcotics list and reclassify it as an ordinary prescription medicine means imposing more restrictive requirements on it than on other drugs — without adequate justification — runs directly into a Federal Constitutional Court that has a consistent record of striking down inconsistent legislation. A referral to the European court on related cannabis advertising restrictions is already in motion, further constraining the government’s options.

Dirk Heitepriem, president of the German Cannabis Business Association, raised a second regulatory threat: a separate proposal to end public health insurance reimbursement for cannabis flowers. He described it as targeting precisely the most vulnerable patients — those with the most serious conditions who depend on reimbursed access. With the cost to statutory insurers negligible relative to the overall healthcare budget, he framed the move as political calculation rather than fiscal necessity.

A Supply Chain Quality Gap

The genetics and cultivation session addressed a different business liability — quality failures built into the production cycle itself.

Arjan Roskam of Green House Genetics described the post-harvest problem as pervasive: “Nine out of ten producers are cutting corners, drying in six, seven, eight days when everybody knows you need 14.” Dave Auger of Big League Genetics added that regulatory fragmentation across EU markets compounds the issue — products navigating multiple national standards can travel for months before reaching patients, degrading freshness and potency alike.

Adele Hollman, medical affairs manager at Sanity Group, identified the structural root: the near-total absence of a feedback loop from patient outcomes back to breeders. Without that data, consistent therapeutic results are difficult to engineer and clinical evidence for regulators is hard to build. Consistent genetics and post-harvest standards are not just a quality question; they are a market-access question, as Jersey’s medical cannabis producers have found seeking export credibility into European markets with demanding standards.

Women’s Health Finds Its Regulatory Opening

The panel on cannabis and women’s health made the case that an underserved patient population is finding regulatory recognition — if not yet the products it needs.

In January 2025, the Illinois Department of Public Health approved four conditions for medical cannabis treatment — endometriosis, ovarian cysts, uterine fibroids, and female orgasmic disorder — the first expansion of Illinois’s qualifying conditions list since 2019 and the first to add explicitly gender-specific conditions. Suzanne Mulvehill of the Female Orgasm Research Institute described the advocacy path: eight US states rejected the petition before two approved it; Illinois then became the first to legislate the category.

Dr Grace Blest-Hopley, Chief Science Officer at Hystelica, explained the pharmacological case. Oestrogen and progesterone directly modulate the endocannabinoid system, meaning women’s cannabinoid response varies across the menstrual cycle and shifts through perimenopause — a complexity that existing products are not designed around. The UK market, she said, is nearly entirely high-THC flower, poorly suited to patients who have work and caregiving demands during the day.

The product-market mismatch creates a commercial opening for operators willing to develop formats — lower-THC preparations, alternative delivery methods — designed around women’s use patterns. The companies building clinical credibility in specific patient populations are better positioned for the next competitive phase than those competing on commodity flower volume alone.